(MENAFN- GlobeNewsWire - Nasdaq) BOULDER, Colo., Nov. 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced that Nichoals Saccomano, Ph.D., President and Chief Executive Officer, will present and be available for one-on-one investor meetings at the following investor conferences:

• A fireside chat at the Guggenheim Healthcare Innovation Conference, in Boston on Monday, November 10, 2025, at 4:00 p.m. ET. A live audio webcast will be available through this link
  
• A corporate presentation at the Stifel Healthcare Conference, in New York on November 12, 2025, at 4:00 p.m. ET. A live audio webcast will be available through this link
  
• A fireside chat at the Evercore Healthcare Conference, in Miami on December 3, 2025, at 12:30 p.m. ET. A live audio webcast will be available through this link
  

  Following the events, replays will be available on the OnKure website (click here ) for 30 days.

  About OnKure Therapeutics

  OnKure Therapeutics, Inc. (Nasdaq: OKUR) is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, OnKure is building a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability. OnKure is currently developing OKI-219, a selective PI3Kα^H1047R inhibitor, as its lead program. OnKure aims to become a leader in targeting oncogenic or pathologically activated PI3Kα and has multiple programs designed to enable best-in-class targeting of this key disease creating gene.

  For more information about OnKure, visit us at and follow us on LinkedIn.

  Contact:

  Dan Ferry
  LifeSci Advisors
  ...

  
  

MENAFN04112025004107003653ID1110295547